ARDX - Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday January 8 | Benzinga
WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will host a live event and webcast on Monday, January 8, 2024, at 7:00 p.m. ET / 4:00 p.m. PT. The event will include a management update on IBSRELA® (tenapanor), the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C), as well as a Key Opinion Leader discussion regarding the IBS-C treatment landscape with Philip Schoenfeld, M.D., MS Ed, MSc, Chief (Emeritus) of the Gastroenterology Section at the John D. Dingell VA Medical Center in Detroit, Mich.
The event is being held at Convene, located at 100 Stockton Street, San Francisco, Calif. and will be webcast live. A link to the webcast can be accessed on the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call. To attend the event or submit a question, please contact investor@ardelyx.com.
IMPORTANT SAFETY INFORMATION